SHYNDEC(SH:600420) Shang Hai Zheng Quan Bao·2025-07-17 19:22Financial Performance Summary - In the first half of 2025, the company achieved operating revenue of 487,767.35 million RMB, a decrease of 18.16% compared to the same period last year [4] - The net profit attributable to shareholders of the listed company was 67,206.69 million RMB, down 6.46% year-on-year [4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 63,746.03 million RMB, a decline of 6.72% compared to the previous year [4] Business Operations Analysis - The decline in revenue was influenced by market supply and demand, with lower sales and prices for certain penicillin raw materials and intermediates [4] - The formulation business faced challenges, with sales revenue for some cephalosporins, hormone products, and neurological products decreasing due to centralized drug procurement and reduced terminal demand [4] - The company is focusing on strategic layout, actively promoting research and development, and enhancing market penetration while effectively reducing costs and expenses, which has stabilized profit margins [4]